INBP — Integrated Biopharma Balance Sheet
0.000.00%
Last trade - 00:00
- $6.92m
- $4.92m
- $50.67m
- 65
- 96
- 28
- 66
2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Short Term Investments | 0.475 | 0.402 | 0.21 | 0.331 | 1.32 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 4.44 | 5.51 | 5.78 | 4.89 | 4.51 |
Total Inventory | |||||
Total Other Current Assets | |||||
Total Current Assets | 14.1 | 16.5 | 18 | 16.6 | 16.4 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 5.06 | 4.52 | 4.11 | 3.78 | 4.28 |
Other Long Term Assets | |||||
Total Assets | 19.8 | 22.9 | 25.4 | 25.3 | 25.4 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Current Liabilities | 12.4 | 13.1 | 9.24 | 5.26 | 4.83 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 17.9 | 16.9 | 11.1 | 6.67 | 6.57 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Total Equity | 1.89 | 6.07 | 14.3 | 18.6 | 18.9 |
Total Liabilities & Shareholders' Equity | 19.8 | 22.9 | 25.4 | 25.3 | 25.4 |
Total Common Shares Outstanding |